Pardes Biosciences (NSDQ:PRDS) said its PBI-0451 twice-daily COVID-19 pill candidate had favorable tolerability and good oral bioavailability, based on interim data from an ongoing Phase 1 trial. The company also said the drug candidate lacked clinically significant drug-drug interactions. “We’re very encouraged by the safety profile and bioavailability profile we’re seeing to date,” Brian Kearney,…
The top 5 drug discovery articles of 2021
The pandemic continued to remake the pharma and biotech industry this past year. A handful of companies fared exceptionally well at commercializing COVID-19 therapies. This fact promises to lead to sizable shifts in the rankings of pharma leaders. These trends were not yet evident in our spring roundup of the 50 largest pharma companies, which…
Pardes Biosciences gets patent related to SARS-CoV-2 antiviral
Pardes Biosciences, a biopharma upstart based in Carlsbad, California, has announced that the U.S. Patent and Trademark Office has issued a new patent No. 11,124,497. The patent relates to compounds intended to inhibit the main protease (Mpro) of SARS-CoV-2. “This issued patent is the first from our growing IP portfolio and reflects our commitment to…
An inside look at Pardes Biosciences’ oral coronavirus protease inhibitor
Two months after exiting stealth mode via a SPAC merger, the early-stage biopharma Pardes Biosciences (Palo Alto, California) has launched a first-in-human trial for its investigational COVID-19 pill PBI-0451. The origins of the company stretch back to the early days of the pandemic, said Dr. Uri Lopatin, CEO and co-founder of the company. A visiting…
Pardes Biosciences launches first-in-human trial for SARS-CoV-2 antiviral
A handful of companies may have a lock on COVID-19 vaccines, but competition is heating up in antivirals targeting the novel coronavirus. One of the latest entrants is Pardes Biosciences (Carlsbad, Calif.), which recently announced a Phase 1 trial for PBI-0451, an oral antiviral targeting SARS-CoV-2. Other companies developing antivirals for COVID-19 include Pfizer as well as…